Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Hormonal therapy for advanced prostatic carcinoma.

A D Seftel¹, J P Spirnak, M I Resnick

¹Division of Urology, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106.

Journal of Surgical Oncology. Supplement

|January 1, 1989

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pelvic organ prolapse is associated with alteration of sphingosine-1-phosphate/Rho-kinase signalling pathway in human vaginal wall.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2015

Same author

Effect of once-daily tadalafil on confidence and perceived difficulty in performing sexual intercourse in men who were incomplete responders to as-needed PDE5 inhibitor treatment.

International journal of clinical practice·2014

Same author

The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician.

International journal of clinical practice·2013

Same author

Retrospective analysis of the efficacy and safety of once-daily tadalafil in patient subgroups: men with mild vs moderate ED and aged <50 vs 50 years.

International journal of impotence research·2012

Same author

Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data.

International journal of clinical practice·2012

Same author

Erectile dysfunction and testosterone screening with prostate specific antigen screening at age 40: are these three gender specific determinants additive for overall men's heath and do they improve traditional non-gender specific determinants to lessen cardiovascular risk and all-cause mortality?

International journal of clinical practice·2010

Hormonal therapy remains the standard for advanced prostate cancer. Newer drugs and total androgen blockade show no survival benefit over established treatments like orchiectomy or diethylstilbestrol.

Area of Science:

Oncology
Urology
Endocrinology

Background:

Hormonal therapy, including orchiectomy and estrogens, is the established treatment for advanced prostate cancer.
Newer therapeutic agents have been developed to improve outcomes and reduce side effects compared to traditional hormonal therapy.

Purpose of the Study:

To review newer agents for advanced prostate cancer treatment.
To evaluate the efficacy and survival advantage of novel therapies against standard hormonal treatments.
To assess the benefits of total androgen blockade versus standard androgen blockade.

Main Methods:

Review of existing literature on newer pharmacological agents for advanced prostate cancer.
Comparative analysis of survival data for novel agents versus established hormonal therapies (orchiectomy, diethylstilbestrol).

Related Experiment Videos

Examination of the concept and clinical impact of total androgen blockade.

Main Results:

Newer agents, despite specific effects, do not demonstrate a survival advantage over diethylstilbestrol or orchiectomy.
Total androgen blockade does not offer a survival advantage compared to standard androgen blockade in advanced prostate cancer.

Conclusions:

Current evidence suggests that newer drugs and total androgen blockade do not surpass the survival benefits of established hormonal therapies for advanced prostate cancer.
Diethylstilbestrol and orchiectomy remain benchmarks for treatment efficacy in advanced prostate adenocarcinoma.